Cilengitide companion diagnostic - MDxHealth

Drug Profile

Cilengitide companion diagnostic - MDxHealth

Alternative Names: PredictMDx™ for Glioblastoma

Latest Information Update: 31 Aug 2015

Price : $50

At a glance

  • Originator MDxHealth
  • Developer MDxHealth; Merck KGaA
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 09 Jun 2011 Phase-III clinical trials in Glioblastoma in European Union (Ex vivo)
  • 09 Jun 2011 Phase-III clinical trials in Glioblastoma in USA (Ex vivo)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top